Beam Therapeutics (BEAM) Other Accumulated Expenses (2020 - 2026)

Beam Therapeutics (BEAM) has 7 years of Other Accumulated Expenses data on file, last reported at $9.2 million in Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $9.2 million, up 166.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $9.2 million (up 166.91% YoY), and the FY2025 annual result was $2.0 million, down 74.59% from the prior year.
• Other Accumulated Expenses grew to $9.2 million in Q1 2026 per BEAM's latest filing, from $2.0 million in the prior quarter.
• Over five years, Other Accumulated Expenses peaked at $28.6 million in Q4 2023 and troughed at $2.0 million in Q4 2025.
• A 5-year average of $10.2 million and a median of $7.8 million in 2024 frame the typical range for Other Accumulated Expenses.
• The sharpest annual moves came in 2024 and 2025: Other Accumulated Expenses soared 212.95% in 2024, then slumped 90.49% in 2025.
• A 5-year view of Other Accumulated Expenses shows it stood at $12.3 million in 2022, then soared by 133.58% to $28.6 million in 2023, then sank by 72.73% to $7.8 million in 2024, then plunged by 74.59% to $2.0 million in 2025, then soared by 361.21% to $9.2 million in 2026.
• Business Quant data shows BEAM's Other Accumulated Expenses at $9.2 million in Q1 2026, $2.0 million in Q4 2025, and $2.7 million in Q3 2025.